U.K. company GW Pharmaceuticals has revealed how much their new epilepsy drug Epidiolex will cost. Epidiolex was approved for use in the U.S. by the Food and Drug Administration in June. The drug is the first medication derived from cannabis to receive approval from the agency.
Cost Revealed in Investor Call
In a conference call with investors on Tuesday, the company announced that Epidiolex will cost each patient about $32,500 per year. The estimate is based on assumptions of average patient weight and dosage. The company said the cost was comparable to that of other drugs used to treat severe forms of epilepsy.
During the conference call, GW Pharmaceutical CEO Justin Gover said Epidiolex will provide a reliable and safe cannabinoid treatment for patients.
“This first U.S. approval not only represents a transformative milestone for our company but a historic medical breakthrough, offering patients and their families the first and only FDA approved CBD medicine to treat two severe, childhood-onset epilepsies,” Gover said. “These deserving patients will soon have access to a cannabinoid medicine that has been thoroughly studied in clinical trials, manufactured to assure quality and consistency, and available by prescription under a physician’s care.”
GW Pharmaceuticals North American